United States Government Publishing Office publisher pbl distributor dst United States National Archives and Records Administration Office of the Federal Register author aut Government Organization text government publication eng FR Regulatory Information 2017_register executive 2017-04-03 article Notices D09002ee1c7f21776 D09002ee1c7f21844 United States Department of Health and Human Services originator org United States Government Agency or Subagency United States National Institutes of Health originator org United States Government Agency or Subagency The National Heart, Lung, and Blood Institute (NHLBI), an institute of the National Institutes of Health; an agency within the Department of Health and Human Services, is contemplating the grant of an exclusive patent license to commercialize the invention(s) embodied in the intellectual property estate stated in the Summary Information section of this notice to Corvidia Therapeutics Inc. (Corvidia) located in Waltham, MA and incorporated under the laws of Delaware. 82 FR 16405 https://www.govinfo.gov/app/details/FR-2017-04-04/2017-06546 2017-06546 fr04ap17-66 4140-01-P https://www.govinfo.gov/app/details/FR-2017-04-04/2017-06546 https://www.govinfo.gov/content/pkg/FR-2017-04-04/html/2017-06546.htm https://www.govinfo.gov/content/pkg/FR-2017-04-04/pdf/2017-06546.pdf 2 p. 16405 16406 82 FR 16405 Prospective Grant of Exclusive Patent License: Development and Commercialization of Peptides Promoting Lipid Efflux for the Treatment of Hypertriglyceridemia, With or Without Concomitant Metabolic Syndrome; Federal Register Vol. 82, Issue NOTICE 2017-06546 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health 2017-04-19 4140-01-P 2017-06546 Notice.

The National Heart, Lung, and Blood Institute (NHLBI), an institute of the National Institutes of Health; an agency within the Department of Health and Human Services, is contemplating the grant of an exclusive patent license to commercialize the invention(s) embodied in the intellectual property estate stated in the Summary Information section of this notice to Corvidia Therapeutics Inc. (Corvidia) located in Waltham, MA and incorporated under the laws of Delaware.

Only written comments and/or applications for a license which are received by the NHLBI Office of Technology Transfer and Development on or before April 19, 2017 will be considered. Prospective Grant of Exclusive Patent Licenses: Development and Commercialization of Peptides Promoting Lipid Efflux for Treatment of Hypertriglyceridemia, With or Without Concomitant Metabolic Syndrome , thalhamc@mail.nih.gov Vol. 82, no. 63 Office of the Federal Register, National Archives and Records Administration 2017-04-04 continuing daily deposited born digital 232 p. Table of Contents: AE 2.7: GS 4.107: AE 2.106: KF70.A2 https://www.govinfo.gov/app/details/FR-2017-04-04 P0b002ee1945e8aca 0097-6326 0042-1219 0364-1406 769-004-00000-9 000582072 f:fr04ap17 https://www.govinfo.gov/app/details/FR-2017-04-04 https://www.govinfo.gov/content/pkg/FR-2017-04-04/pdf/FR-2017-04-04.pdf https://www.govinfo.gov/content/pkg/FR-2017-04-04/xml/FR-2017-04-04.xml fdlp 16287 16508 DGPO 2017-04-03 2024-06-01 FR-2017-04-04 machine generated eng FR FR-2017-04-04 82 63